New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Researchers identify potential genetic variants linked to increased cancer risk in children with birth defects

Researchers identify potential genetic variants linked to increased cancer risk in children with birth defects

by Children's Hospital of PhiladelphiaDemographic information of the cohort. aPhenotype information of the discovery cohort; bPhenotype information of the validation cohort; c&nbs
Oncology February 01,2024
Researchers identify potential genetic variants linked to increased cancer risk in children with birth defects

Researchers identify potential genetic variants linked to increased cancer risk in children with birth defects

by Children's Hospital of PhiladelphiaDemographic information of the cohort. aPhenotype information of the discovery cohort; bPhenotype information of the validation cohort; c&nbs
Oncology February 01,2024
Study identifies potential combination therapy for testing in deadly brain cancer

Study identifies potential combination therapy for testing in deadly brain cancer

by Ludwig Cancer ResearchGraphical abstract. Credit:Cancer Cell(2022). DOI: 10.1016/j.ccell.2022.08.014A Ludwig Cancer Research study has identified a combination of three existing dr
Oncology February 01,2024
Study identifies potential combination therapy for testing in deadly brain cancer

Study identifies potential combination therapy for testing in deadly brain cancer

by Ludwig Cancer ResearchGraphical abstract. Credit:Cancer Cell(2022). DOI: 10.1016/j.ccell.2022.08.014A Ludwig Cancer Research study has identified a combination of three existing dr
Oncology February 01,2024
How a patient with kidney cancer overcame several metastases against all expectations

How a patient with kidney cancer overcame several metastases against all expectations

by The Spanish National Cancer Research CentreGraphical abstract. Credit:International Journal of Cancer(2023). DOI: 10.1002/ijc.3457515 years ago, a woman in her thirties was diagnos
Oncology February 01,2024
How a patient with kidney cancer overcame several metastases against all expectations

How a patient with kidney cancer overcame several metastases against all expectations

by The Spanish National Cancer Research CentreGraphical abstract. Credit:International Journal of Cancer(2023). DOI: 10.1002/ijc.3457515 years ago, a woman in her thirties was diagnos
Oncology February 01,2024
New findings on therapy-related myeloid cancers

New findings on therapy-related myeloid cancers

by Sylvester Comprehensive Cancer CenterCredit:Blood(2022). DOI: 10.1182/blood-2022-158992Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Me
Oncology February 01,2024
New findings on therapy-related myeloid cancers

New findings on therapy-related myeloid cancers

by Sylvester Comprehensive Cancer CenterCredit:Blood(2022). DOI: 10.1182/blood-2022-158992Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Me
Oncology February 01,2024
Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainNovel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnose
Oncology February 01,2024
Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainNovel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnose
Oncology February 01,2024
First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral cris
Oncology February 01,2024
First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral cris
Oncology February 01,2024
An elusive mechanism of wasting syndrome cachexia revealed

An elusive mechanism of wasting syndrome cachexia revealed

by Justin Jackson , Medical XpressOSM induces Eda2r expression in muscle and the depletion of OSMR protects from muscle wasting. a, Mouse primary myotubes were treated with recombinant TNFα, IL-6, LIF
Oncology February 01,2024
An elusive mechanism of wasting syndrome cachexia revealed

An elusive mechanism of wasting syndrome cachexia revealed

by Justin Jackson , Medical XpressOSM induces Eda2r expression in muscle and the depletion of OSMR protects from muscle wasting. a, Mouse primary myotubes were treated with recombinant TNFα, IL-6, LIF
Oncology February 01,2024
Study: Tumor necroptosis promotes metastasis by modulating tumor-host immunity

Study: Tumor necroptosis promotes metastasis by modulating tumor-host immunity

by Impact Journals LLCTumor necroptosis promotes metastasis of breast cancer by suppressing anti-tumor immunity. Credit: 2023 Liu et al.A new editorial paper was published inOncotarget's&nbs
Oncology February 01,2024
Study: Tumor necroptosis promotes metastasis by modulating tumor-host immunity

Study: Tumor necroptosis promotes metastasis by modulating tumor-host immunity

by Impact Journals LLCTumor necroptosis promotes metastasis of breast cancer by suppressing anti-tumor immunity. Credit: 2023 Liu et al.A new editorial paper was published inOncotarget's&nbs
Oncology February 01,2024
A HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy

A HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy

by Compuscript LtdSchematic diagram and pharmacokinetics of HER2-TP-cy5.5 and HER-TA-cy5.5 conjugate synthesis. (A) Schematic representation of the utilization of HER2-targeting peptide/antibody and C
Oncology February 01,2024
A HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy

A HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy

by Compuscript LtdSchematic diagram and pharmacokinetics of HER2-TP-cy5.5 and HER-TA-cy5.5 conjugate synthesis. (A) Schematic representation of the utilization of HER2-targeting peptide/antibody and C
Oncology February 01,2024
Can an annual blood test find cancer while it's curable?

Can an annual blood test find cancer while it's curable?

by Lisa M. KriegerCredit: Unsplash/CC0 Public DomainDespite decades of effort in the war against cancer, screening tests are available for only five types of the disease, representing less than one-th
Oncology February 01,2024
Can an annual blood test find cancer while it's curable?

Can an annual blood test find cancer while it's curable?

by Lisa M. KriegerCredit: Unsplash/CC0 Public DomainDespite decades of effort in the war against cancer, screening tests are available for only five types of the disease, representing less than one-th
Oncology February 01,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com